Roche's oral SERD flunks phase 3 trial in 1st-line breast cancer, raising questions of mechanism's limits
Roche's oral SERD flunks phase 3 trial in 1st-line breast cancer, raising questions of mechanism's limits
Body unavailable. Use the original source.